Photo of Tom Rosenberg, MD

Tom Rosenberg, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-4902


tom_rosenberg@dfci.harvard.edu

Photo of Tom Rosenberg, MD

Dana-Farber Cancer Institute
Phone: (617) 632-4902


tom_rosenberg@dfci.harvard.edu

Visualize Collaborations

Tom Rosenberg, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Instructor, Pediatrics, Harvard Medical School
  • Attending physician, Pediatric Oncology, Dana-Farber Cancer Institute

HCC PROGRAM AFFILIATION

Research Abstract

My research interest is the treatment of infant brain tumors, with a focus on atypical teratoid rhabdoid tumors (ATRT). I am involved in the development of clinical trials both for newly diagnosed and recurrent ATRT, with both projects involving a multi-institutional collaboration. In addition, I am leading a pilot study to test the feasibility of detecting CSF derived circulating tumor DNA and validating these findings as biomarkers for treatment response and risk of recurrence.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Rosenberg T, Cooney T. Current Open Trials and Molecular Update for Pediatric Embryonal Tumors. Pediatr Neurosurg 2023. PubMed
  • Rosenberg T, Bandopadhayay P. Molecular genetics of paediatric brain tumours and opportunities for precision medicine - a focus on infant tumours. Curr Opin Neurol 2022; 35:772-778. PubMed
  • Rosenberg T, Yeo KK, Mauguen A, Alexandrescu S, Prabhu SP, Tsai JW, Malinowski S, Joshirao M, Parikh K, Farouk Sait S, Rosenblum MK, Benhamida JK, Michaiel G, Tran HN, Dahiya S, Kachurak K, Friedman GK, Krystal JI, Huang MA, Margol AS, Wright KD, Aguilera D, MacDonald TJ, Chi SN, Karajannis MA. Upfront Molecular Targeted Therapy for the Treatment of BRAF-Mutant Pediatric High-Grade Glioma. 2022. PubMed
Visualize Collaborations